The presence of autoantibodies against a calcium channel in people with amyotrophic lateral sclerosis (ALS) may explain the frequent development of type 2 diabetes in these patients, a preclinical study suggests. The data, which pinpoint the toxic effects of these autoantibodies in mouse insulin-secreting pancreatic cells, shed light on…
News
Kevin Schaefer hadn’t been in an airport since he was 4 years old, so he had been looking forward to flying from his home in Cary, North Carolina, to Anaheim, California, in June for the 2019 Cure SMA Conference. As it turned out, his experience didn’t go as expected.
News
AI-based Platform Suggests Cancer Candidate LAM-002 as Possible ALS Therapy, AI Therapeutics Says
AI Therapeutics‘ lymphoma candidate LAM-002 was identified by the company’s artificial intelligence-based platform — called Guardian Angel — as a possible treatment for amyotrophic lateral sclerosis (ALS). Researchers from AI have already tested and confirmed LAM-002’s therapeutic potential in an ALS context. Now, an independent…
A $1 million gift from the Manouk Djoukhadjian Family Foundation II will create Quebec’s first philanthropic research chair on amyotrophic lateral sclerosis (ALS). The donation to the Armand-Frappier Foundation will establish the Anna Sforza Djoukhadjian Philanthropic Research Chair to advance ALS research at the Institut national…
Stealth BioTherapeutics announced the initiation of a Phase 1 trial to assess the safety and tolerability of its investigational oral treatment, SBT-272, in healthy volunteers. SBT-272 is being developed to treat neurodegenerative diseases marked by problems in the workings of mitochondria (a cell’s powerhouse), including amyotrophic lateral sclerosis…
The U.S. Food and Drug Administration (FDA) has authorized the evaluation of the first three candidate therapies for amyotrophic lateral sclerosis (ALS) in the HEALEY ALS Platform Trial. This trial model, designed to accelerate the development of ALS therapies by assessing multiple treatment candidates simultaneously, is the first of…
Athletes who played professional football — known as soccer in the U.S. — are more than three times more likely to die of a neurodegenerative disease than are the general population, a study from Scotland has found. Its researchers compared causes of death over 18 years for about 7,700 former professional…
A first patient has been dosed in a Phase 2 trial testing a nanomedicine called CNM-Au8 as a potentially disease-modifying therapy for people with amyotrophic lateral sclerosis (ALS). This safety and efficacy study, due to finish in April 2021, is also completely enrolled, Clene Nanomedicine, the treatment’s developer, announced…
A single spinal injection of an investigational RNA therapy blocked motor neuron degeneration and saved motor function in animal models of familial amyotrophic lateral sclerosis (ALS) linked to SOD1 mutations, a study reports. Giving the treatment — a virus-delivered gene-silencer targeting the SOD1 gene — before the onset of…
A recently discovered inflammatory mechanism triggered by Schwann cells — specialized cells that produce the protective myelin sheath around neurons — in amyotrophic lateral sclerosis (ALS) can be alleviated with masitinib, a study in rat models shows. The study, “Schwann cells orchestrate peripheral nerve…
Recent Posts
- Higher physical activity tied to lower ALS risk in large UK study
- Those earlier years with ALS seem like a different life
- Frailty-based screening tool may help flag people at higher risk of ALS
- How I learned to live — and thrive — with ALS
- Stem cell therapy may slow ALS functional decline, researchers say